The patients who comprised this study, Kwith few exceptions, had moderate or severe hypertension, usually diagnosed as "essential" hypertension, but in some instances as "renal." There were no cases of "malignant" hypertension, as usually considered. The patients were divided into two series.
D ESPITE the present availability of a number of effective hypotensive drugs, none appears to possess the features of the ideal therapeutic depressor agent.' An adequate persistent hypotensive response can be induced only in a limited number of patients with the less powerful drugs, and dangerous side effects limit the usefulness of the more powerful depressor agents. Thus, various combinations of such drugs appear to be safer and more effective than any one used alone.2 Recently, Wilkins and Judson3 introduced Rauwolfia serpentina into this country, a drug which appears to be a valuable addition to the therapeutic armamentarium available for the treatment of hypertension and its complications. In preliminary studies we have been able generally to confirm their findings concerning the hypotensive and other effects of this drug. Wilkins1 ' 2 has suggested that the combination of hydrazinophthalazine (hydralazine) and Rauwolfia serpentina appears to be one of the safer depressor combinations, permitting an ease of oral administration and patient follow-up not possible with various other combinations of hypotensive agents. The present study is concerned with determining the clinical usefulness of this particular combination of drugs in the routine treatment of both hospitalized and office patients with hypertension. 
MATERIAL AN-D METHODS
The patients who comprised this study, Kwith few exceptions, had moderate or severe hypertension, usually diagnosed as "essential" hypertension, but in some instances as "renal." There were no cases of "malignant" hypertension, as usually considered. The patients were divided into two series.
The first series consisted of 13 merchant seamen with known persistent severe hypertension for periods of time ranging from at least 6 months to over 10 years. These men had been previously under both outpatient and inpatient medical care. All patients were hospitalized for the purpose of this study and their hypertensive state carefully reevaluated under routine hospital conditions, while ambulatory and at bed rest. The patients were permitted ambulatory status on the ward wvhile under observation. Each patient had a (complete history and physical examination and laboratory studies which included complete blood counts and determination of the sedimentation rate, urinalysis and stain of the urinary sediment for "Steniilieiimier cells,"4 renal concentration and dilution tests, determination of nonprotein nitrogen, fractional phenolsulfonphthalein test, chest x-ray examination and cardiac fluoroscopy, intravenous pyelography, electrocardiogram and ballistocardiogram. Observations of blood pressure and pulse rate were recorded at least twice daily under standardized conditions, and general symptomatology was noted at each of these periods. There were four instances of apparent "renal" hypertension associated with chronic pyelonephritis.
After usually four or more weeks of control observation, the patients were given Rauwolfia It is of interest that therapy was effective in these two patients, but was less effective despite a larger dosage of hydralazine in case 5 where severe, fixed hypertension, known for many years, had failed to respond to a sympathectomy performed five years ago. The remaining patients presented evidence of chronic pyelonephritis. The results of therapy were excellent in case 2 and Raulwolfia alone served to reduce the blood pressure effectively in cases 3 and 7. Patient 6 had only a fair result, which was not improved by further increasing the dosage of hydralazine.
A reduction of the pulse rate, often to bradycardic levels, occurred in many of the ambulatory groups of patients. Nasal congestion was observed in some of the patients but was troublesome in only one instance. Significant increase of bowel frequency occurred in one patient who had a history of "irritable colon" syndrome. No serious side effects occurred in any patient, although increased angina was observed in one instance, preventing a larger and probably more effective dosage of hydralazine. In contrast to an earlier experience with hydralazine used alone, it was observed that the prior administration of Rauwolfia markedly reduced the incidence and severity of palpitation, tachycardia, and "headache" commonly observed when initiating treatment with hydralazine, and permitted administration of the latter in an initial dosage of 25 to 50 mg. given three times daily. Finally, although precise comparative studies were not performed in this group of patients, it is our definite impression that the concomitant administration of Rauwolfia and hydralazine induces a degree of blood pressure reduction which would require substantially larger doses of hydralazine if used alone, doses more prone to induce serious side effects and more difficult to control. We have also been impressed with the favorable effects of Rauwolfia upon the anxiety, general tension and other symptoms prone to occur in hypertensive patients.
DIscussIoN
Rauwolfia serpentina has been used in India for over 10 
